Fulcrum Therapeutics (FULC) AI Stock Analysis

• Market Cap: $452.97M
• Dividend Yield: N/A
• Average Volume (3M): 501.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.42
• Revenue Growth: -100.00%
• EPS Growth: -305.92%
• Country: US
• Employees: 45
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 54,118,440
• 10 Day Avg. Volume: 395,939
• 30 Day Avg. Volume: 501,706
• PEG Ratio: 0.33
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 3.64
• P/FCF Ratio: -116.72
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -334.47
• Enterprise Value/Ebitda: -3.09
• 1Y Price Target: $13.88
• Price Target Upside: 43.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: $10.50 ▲(8.81% Upside)

Fulcrum Therapeutics' overall stock score reflects strong technical indicators and promising clinical developments, which are offset by ongoing financial challenges. The company's robust balance sheet and positive trial results provide a solid foundation for future growth, but operational profitability remains a key area for improvement.

Positive Factors

Clinical Progress

The promising results from the Phase Ib PIONEER trial for pociredir in sickle cell disease indicate strong potential for future therapeutic success, enhancing Fulcrum's market position in treating genetic diseases.

Financial Position

A strong cash position provides Fulcrum with the financial flexibility to continue its R&D efforts and operations through 2028, supporting long-term strategic initiatives and reducing financial risk.

Pipeline Expansion

The planned IND submission for bone marrow failure syndromes reflects Fulcrum's strategic expansion into new therapeutic areas, potentially broadening its market reach and diversifying its product pipeline.

Negative Factors

Cash Reserve Decrease

The significant decrease in cash reserves highlights ongoing operational costs and financial strain, which could impact Fulcrum's ability to sustain long-term R&D activities without additional funding.

Net Loss

Continued net losses reflect challenges in achieving operational profitability, which may hinder Fulcrum's ability to invest in future growth and development without external capital.

Revenue Growth Challenges

A significant decline in revenue growth indicates potential difficulties in commercializing products, which could affect Fulcrum's long-term financial health and market competitiveness.

Fulcrum Therapeutics Business Overview & Revenue Model

Company Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Fulcrum Therapeutics generates revenue primarily through the development and commercialization of its therapeutic candidates. The company may earn money through several key revenue streams, including partnerships and collaborations with larger pharmaceutical companies, milestone payments upon reaching specific development and regulatory achievements, and royalties from future sales of any marketed products. Additionally, Fulcrum may receive funding through grants or research grants that support its development programs, further contributing to its financial sustainability.

Fulcrum Therapeutics Financial Statement Overview

Summary

Fulcrum Therapeutics shows strong revenue stability and gross profit margin, supported by a robust balance sheet with low leverage and high equity. However, challenges remain in achieving operational profitability and cash flow sustainability due to consistent net losses.

Income Statement

Fulcrum Therapeutics shows a stable revenue over the TTM period with $80M, but the company is struggling with negative net income at -$510,000 and a significant negative EBIT margin of -15.58%. The company's gross profit margin is strong at 78.42%, indicating good cost control over production, but the high operating losses need addressing to improve profitability.

Balance Sheet

The balance sheet of Fulcrum Therapeutics is robust, with a high equity ratio of 94.15% and low debt-to-equity ratio of 0.04, indicating minimal reliance on debt. The company's stockholders' equity stands strong at $228.49M, providing a solid financial foundation. However, the company needs to focus on converting this equity strength into operational profitability.

Cash Flow

Fulcrum Therapeutics shows improvement in cash flow with a positive operating cash flow of $7.81M in the TTM period, turning around from previous negative cash flows. The free cash flow is also positive at $7.56M, indicating better cash management. However, the operating cash flow to net income ratio is not sustainable at 15.31 due to negative net income, which suggests future cash flow stability is uncertain.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	80.00M	2.81M	6.34M	19.16M	8.82M
Gross Profit	-669.00K	78.41M	2.81M	-70.44M	-50.54M	-50.22M
EBITDA	-72.45M	-18.24M	-108.49M	-109.72M	-78.54M	-69.23M
Net Income	-71.11M	-9.72M	-97.33M	-109.87M	-80.85M	-70.82M
Balance Sheet
Total Assets	214.86M	260.72M	257.69M	226.69M	235.00M	129.58M
Cash, Cash Equivalents and Short-Term Investments	200.65M	241.02M	236.22M	202.92M	218.16M	112.91M
Total Debt	7.01M	8.63M	10.82M	13.42M	0.00	17.00K
Total Liabilities	16.49M	17.68M	22.50M	27.74M	23.46M	34.40M
Stockholders Equity	198.37M	243.03M	235.19M	198.94M	211.54M	95.18M
Cash Flow
Free Cash Flow	-60.41M	-2.50M	-91.47M	-99.01M	-80.19M	-55.00M
Operating Cash Flow	-60.03M	-2.22M	-90.97M	-97.05M	-78.48M	-53.66M
Investing Cash Flow	34.03M	32.23M	-36.69M	12.41M	-129.67M	-57.14M
Financing Cash Flow	448.00K	2.75M	118.12M	84.32M	186.51M	71.13M

Fulcrum Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FULC, the sentiment is Positive. The current price of 9.65 is above the 20-day moving average (MA) of 8.75, above the 50-day MA of 8.56, and above the 200-day MA of 6.17, indicating a bullish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 60.49 is Neutral, neither overbought nor oversold. The STOCH value of 80.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FULC.

Fulcrum Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FULC	63 Neutral	$452.97M	-7.10	-31.21%	―	-100.00%	-305.92%
INBX	55 Neutral	$1.19B	-7.46	-144.07%	―	―	―
GLUE	52 Neutral	$935.09M	44.56	9.28%	―	1112.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MNPR	48 Neutral	$521.24M	―	-26.54%	―	―	-73.48%
ADCT	47 Neutral	$490.55M	―	―	―	6.35%	39.57%
OPT	39 Underperform	$477.76M	-3.01	―	―	-80.09%	60.14%

Fulcrum Therapeutics Corporate Events

Fulcrum Therapeutics’ Earnings Call Highlights Progress and Potential

The recent earnings call for Fulcrum Therapeutics painted a picture of optimism and strategic advancement, despite some financial challenges. The company showcased significant progress in the clinical development of its lead program, pociredir, for sickle cell disease. While there was a noted decrease in cash reserves and continued net losses, the overall sentiment was positive, focusing on achievements and future plans that position Fulcrum well for further advancements.

Fulcrum Therapeutics Reports Q3 2025 Progress and Financials

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing small molecules to treat genetically defined rare diseases, with a particular emphasis on sickle cell disease (SCD). The company utilizes proprietary technology to identify drug targets that can modulate gene expression to address the root causes of these diseases.

Fulcrum Therapeutics Highlights Progress in Sickle Cell Treatment

On August 28, 2025, Fulcrum Therapeutics released an updated corporate presentation highlighting their progress and strategic focus on developing treatments for genetically defined rare diseases. The presentation emphasized the potential of pociredir in treating sickle cell disease, showcasing promising results from their Phase 1b PIONEER study, which demonstrated significant increases in fetal hemoglobin and improvements in key markers of hemolysis. These developments position Fulcrum as a key player in addressing the unmet needs in the SCD treatment landscape, despite recent challenges faced by other therapies in the market.

The most recent analyst rating on (FULC) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Fulcrum Therapeutics stock, see the FULC Stock Forecast page.